Abstract:As the first member of the solute carrier 6 (SLC6) protein family, the γ-aminobutyric acid (GABA) transporter 1 (GAT1, SLC6A1 ), plays a pivotal role in the uptake of GABA from the synaptic cleft into neurons and astrocytes. This process facilitates the subsequent storage of GABA in presynaptic vesicles. The human SLC6A1 gene is highly susceptible to missense mutations, leading to severe clinical outcomes, such as epilepsy, in the afflicted patients. The molecular mechanisms of SLC6A1 -associated disorders are discerned to some degree; many SLC6A1 mutations are now known to impair protein folding, and consequently fail to reach the plasma membrane. Inherently, once inside the endoplasmic reticulum (ER), GAT1 abides by a complex cascade of events that enable efficient intracellular trafficking. This involves association with specialized molecular chaperones responsible for steering the protein folding process, oligomerization, sorting through the Golgi apparatus, and ultimately delivery to the cell surface. The entire process is subject to stringent quality control mechanisms at multiple checkpoints. While the majority of the existing loss-of-function SLC6A1 variants interfere with folding and membrane targeting, certain mutants retain abundant surface expression. In either scenario, suppressed GAT1 activity disrupts GABAergic neurotransmission, preceding the disease manifestation in individuals harboring these mutations. The nervous system is enthralling and calls for systematic, groundbreaking research efforts to dissect the precise molecular factors associated with the onset of complex neurological disorders, and uncover additional non-canonical therapeutic targets. Recent research has given hope for some of the misfolded SLC6A1 variants, which can be salvaged by small molecules, i.e., chemical and pharmacological chaperones, acting on multiple upstream targets in the secretory pathway. We here highlight the significance of pharmacochaperoning as a therapeutic strategy for the treatment of SLC6A1 -related disorders.

Future opportunities in solute carrier structural biology

Computational Chemistry in Structure-Based Solute Carrier Transporter Drug Design: Recent Advances and Future Perspectives

The SLC transporter in nutrient and metabolic sensing, regulation, and drug development

The Solute Carrier Transporters and the Brain: Physiological and Pharmacological Implications.

ATP-Binding Cassette and Solute Carrier Transporters: Understanding Their Mechanisms and Drug Modulation Through Structural and Modeling Approaches

Analysis and update of the human solute carrier (SLC) gene superfamily

Metabolic mapping of the human solute carrier superfamily

Harnessing Solute Carrier Transporters for Precision Oncology

Solute carrier transporters: emerging central players in tumour immunotherapy.

Data- and knowledge-derived functional landscape of human solute carriers

Novel Approaches to Studying SLC13A5 Disease

The solute carrier superfamily interactome

SLC6 transporters: Structure, function, regulation, disease association and therapeutics

Solute Carriers As Potential Oncodrivers Or Suppressors: Their Key Functions In Malignant Tumor Formation

A transporter's doom or destiny: SLC6A1 in health and disease, novel molecular targets and emerging therapeutic prospects

The Role of SLC12A Family of Cation-Chloride Cotransporters and Drug Discovery Methodologies

The Important Role of Transporter Structures in Drug Disposition, Efficacy, and Toxicity.

Defining solute carrier transporter signatures of murine immune cell subsets

Solute carrier transporters: the metabolic gatekeepers of immune cells

SLC7A11/xCT in Cancer: Biological Functions and Therapeutic Implications.

The genetic interaction map of the human solute carrier superfamily